# TolerogenixX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tolerogenixx

- Industry: Biotechnology
- Headquarters: Heidelberg, Germany
- Website: www.tolerogenixx.com
- Latest round: Seed (May 23, 2017)
- Investors on record: 1

## About

TolerogenixX GmbH, based in Heidelberg, Germany, develops personalized cellular therapies designed to induce immune tolerance, primarily targeting organ transplant recipients and patients with autoimmune diseases.Founded in 2016, TolerogenixX GmbH specializes in innovative cellular therapies. The company has engaged in three funding rounds, with the most recent round occurring on July 4, 2023, where they raised EUR 7 million led by DB Speciality Invest GmbH & Co. KG alongside other investors. CEO Matthias Schaier leads the company in advancing clinical applications of their therapies.TolerogenixX GmbH specializes in the development of personalized cellular therapies aimed at achieving sustained immune tolerance, primarily for organ transplant recipients and patients with autoimmune diseases. Their flagship product, MIC-Lx (Modified Immune Cells for Living-donor transplants), utilizes proprietary MIC technology to modify peripheral blood mononuclear cells (PBMCs) from living donors. This therapy aims to induce donor-specific immune tolerance, thus minimizing organ rejection risks and the need for long-term immunosuppression. The company has successfully completed Phase Ib clinical trials and is progressing with ongoing Phase IIb studies, targeting markets where organ transplantation and autoimmune conditions are prevalent.TolerogenixX GmbH is supported by a recent Series A financing round totaling EUR 7 million, reflecting investor confidence in its therapeutic approach. The company's revenue generation primarily stems from partnerships with healthcare institutions and clinical centers that administer its MIC-Lx therapy. Revenue may arise from agreements with hospitals and transplant centers, structured around clinical trials and subsequent commercialization of the therapy.In July 2023, TolerogenixX GmbH raised EUR 7 million in Series A funding to complete Phase II of its clinical program. The company plans to expand its reach into new markets, particularly those with significant organ transplant and autoimmune disease needs, leveraging the recent funding to support further clinical studies and product development. Future product launches are being designed to enhance patient outcomes, with a focus on maintaining a robust clinical development strategy.

## Funding rounds

- Seed, May 23, 2017 — High-Tech Gruenderfonds

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed